Literature DB >> 23171823

Haemophilus influenzae serotype B (Hib) seroprevalence in England and Wales in 2009.

Sn Ladhani1, Me Ramsay, Js Flood, H Campbell, Mp Slack, R Pebody, J Findlow, E Newton, M Wilding, R Warrington, H Crawford, Sy Min, K Gray, S Martin, S Frankland, N Bokuvha, G Laher, R Borrow.   

Abstract

A national seroprevalence study was performed to determine the prevalence of Haemophilus influenzae type b (Hib) antibodies in England and Wales in 2009, when Hib disease incidence was the lowest ever recorded. A total of 2,693 anonymised residual sera from routine diagnostic testing submitted by participating National Health Service hospital laboratories were tested for Hib anti-polyribosyl-ribitol phosphate (PRP) IgG antibodies using a fluorescent bead assay. Median anti-PRP IgG concentrations were highest in toddlers aged 1–4 years (2.65 μg/ml), followed by children aged 5–9 years (1.95 μg/ml). Antibody concentrations were significantly lower after this age, but were still significantly higher among 10–19 year-olds (0.54 μg/ml) compared with adults aged >20 years (0.16 μg/ ml; p<0.0001). Half of the adults (51%) did not have Hib antibody concentrations ≥0.15 μg/ml, the level considered to confer short-term protection. Thus, the current excellent Hib control appears to be the result of high anti-PRP antibody concentrations in children aged up to 10 years, achieved through the various childhood vaccination campaigns offering booster immunisation. The lack of seroprotection in adults emphasises the importance of maintaining control of the disease and, most probably carriage, in children, therefore raising the question as to whether long-term routine boosting of either pre-school children or adolescents may be required.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23171823     DOI: 10.2807/ese.17.46.20313-en

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  5 in total

Review 1.  New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin.

Authors:  R Ameratunga; S-T Woon; D Gillis; W Koopmans; R Steele
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

2.  Evaluation of the safety and immunogenicity in United Kingdom laboratory workers of a combined Haemophilus influenzae type b and meningococcal capsular group C conjugate vaccine.

Authors:  Jamie Findlow; Helen Findlow; Sarah Frankland; Ann Holland; Daniel Holme; Emma Newton; Jo Southern; Pauline Waight; Ed Kaczmarski; Elizabeth Miller; Ray Borrow
Journal:  J Occup Med Toxicol       Date:  2014-07-16       Impact factor: 2.646

Review 3.  Comparison of diagnostic criteria for common variable immunodeficiency disorder.

Authors:  Rohan Ameratunga; Maia Brewerton; Charlotte Slade; Anthony Jordan; David Gillis; Richard Steele; Wikke Koopmans; See-Tarn Woon
Journal:  Front Immunol       Date:  2014-09-15       Impact factor: 7.561

4.  Modelling the effects of booster dose vaccination schedules and recommendations for public health immunization programs: the case of Haemophilus influenzae serotype b.

Authors:  Nadia A Charania; Seyed M Moghadas
Journal:  BMC Public Health       Date:  2017-09-13       Impact factor: 3.295

5.  Immune responses to vaccine-preventable diseases among toddlers and preschool children after primary immunization and first booster in Northwestern Algiers, Algeria.

Authors:  Nabila Benamrouche; Hassiba Tali Maamar; Samia Chemli; Houria Senouci; Kheira Rahal
Journal:  Heliyon       Date:  2018-06-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.